Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment

Molecular Oncology

Volumn 8, Issue 1, 2014, Pages 59-67

  Kjersem, J B ^a   Ikdahl, T ^a   Lingjaerde, O C ^b   Guren, T ^a   Tveit, K M ^a   Kure, E H ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

5 Fluorouracil; Circulating microrna; Metastatic colorectal cancer; Oxaliplatin; Predictive markers

Indexed keywords

FLUOROURACIL; IRINOTECAN; MICRORNA; MICRORNA 106A; MICRORNA 130B; MICRORNA 484; OXALIPLATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; UPREGULATION;

5-FLUOROURACIL; CIRCULATING MICRORNA; METASTATIC COLORECTAL CANCER; OXALIPLATIN; PREDICTIVE MARKERS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COHORT STUDIES; COLON; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RECTUM; TREATMENT OUTCOME;

EID: 84892993914     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.09.001     Document Type: Article

References (51)

1. Andersen C.L., Jensen J.L., Orntoft T.F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004, 64:5245-5250.
2. Arndt G.M., Dossey L., Cullen L.M., Lai A., Druker R., Eisbacher M., Zhang C., Tran N., Fan H., Retzlaff K., Bittner A., Raponi M. Characterization of global microRNA expression reveals oncogenic potential of MiR-145 in metastatic colorectal cancer. BMC Cancer 2009, 9:374.
3. Babashah S., Sadeghizadeh M., Hajifathali A., Tavirani M.R., Zomorod M.S., Ghadiani M., Soleimani M. Targeting of the signal transducer Smo links MicroRNA-326 to the oncogenic Hedgehog Pathway in CD34 CML Stem/Progenitor cells. Int. J. Cancer 2013, 133:579-589.
4. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
5. Boeri M., Verri C., Conte D., Roz L., Modena P., Facchinetti F., Calabro E., Croce C.M., Pastorino U., Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3713-3718.
6. Catela I.T., Aralica G., Cacev T., Loncar B., Kapitanovic S. MiR-106a overexpression and PRB downregulation in sporadic colorectal cancer. Exp. Mol. Pathol. 2013, 94:148-154.
7. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., Arking D.E., Beer M.A., Maitra A., Mendell J.T. Transactivation of MiR-34a by P53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26:745-752.
8. Chen X., Liang H., Zhang J., Zen K., Zhang C.Y. Horizontal transfer of MicroRNAs: molecular mechanisms and clinical applications. Protein Cell 2012, 3:28-37.
9. Cheng H., Zhang L., Cogdell D.E., Zheng H., Schetter A.J., Nykter M., Harris C.C., Chen K., Hamilton S.R., Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011, 6:e17745.
10. Cookson V.J., Bentley M.A., Hogan B.V., Horgan K., Hayward B.E., Hazelwood L.D., Hughes T.A. Circulating MicroRNA profiles reflect the presence of breast tumours but not the profiles of MicroRNAs within the tumours. Cell Oncol. (Dordr.) 2012, 35:301-308.
11. Diaz R., Silva J., Garcia J.M., Lorenzo Y., Garcia V., Pena C., Rodriguez R., Munoz C., Garcia F., Bonilla F., Dominguez G. Deregulated expression of MiR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 2008, 47:794-802.
12. Du C., Liu C., Kang J., Zhao G., Ye Z., Huang S., Li Z., Wu Z., Pei G. MicroRNA MiR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat. Immunol. 2009, 10:1252-1259.
13. Esquela-Kerscher A., Slack F.J. Oncomirs - MicroRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
14. Feng B., Dong T.T., Wang L.L., Zhou H.M., Zhao H.C., Dong F., Zheng M.H. Colorectal cancer migration and invasion initiated by MicroRNA-106a. PLoS One 2012, 7:e43452.
15. Ferretti E., De S.E., Miele E., Laneve P., Po A., Pelloni M., Paganelli A., Di M.L., Caffarelli E., Screpanti I., Bozzoni I., Gulino A. Concerted MicroRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 2008, 27:2616-2627.
16. Giraldez M.D., Lozano J.J., Ramirez G., Hijona E., Bujanda L., Castells A., Gironella M. Circulating MicroRNAs As biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin. Gastroenterol. Hepatol. 2012, 11:681-688.
17. Hansen T.F., Sorensen F.B., Lindebjerg J., Jakobsen A. The predictive value of MicroRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer 2012, 12:83.
18. Hirota T., Date Y., Nishibatake Y., Takane H., Fukuoka Y., Taniguchi Y., Burioka N., Shimizu E., Nakamura H., Otsubo K., Ieiri I. Dihydropyrimidine Dehydrogenase (DPD) expression is negatively regulated by certain MicroRNAs in human lung tissues. Lung Cancer 2012, 77:16-23.
19. Hofsli E., Sjursen W., Prestvik W.S., Johansen J., Rye M., Trano G., Wasmuth H.H., Hatlevoll I., Thommesen L. Identification of Serum MicroRNA profiles in colon cancer. Br. J. Cancer 2013, 108:1712-1719.
20. Huang J.J., Yu J., Li J.Y., Liu Y.T., Zhong R.Q. Circulating MicroRNA expression is associated with genetic subtype and survival of multiple myeloma. Med. Oncol. 2012, 29:2402-2408.
21. Jahid S., Sun J., Edwards R.A., Dizon D., Panarelli N.C., Milsom J.W., Sikandar S.S., Gumus Z.H., Lipkin S.M. MiR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov. 2012, 2:540-553.
22. Karsy M., Arslan E., Moy F. Current progress on understanding MicroRNAs in Glioblastoma multiforme. Genes Cancer 2012, 3:3-15.
23. Kim B.H., Hong S.W., Kim A., Choi S.H., Yoon S.O. Prognostic implications for high expression of oncogenic MicroRNAs in advanced gastric carcinoma. J. Surg. Oncol. 2013, 107:505-510.
24. Kjaer-Frifeldt S., Hansen T.F., Nielsen B.S., Joergensen S., Lindebjerg J., Soerensen F.B., Depont C.R., Jakobsen A. The prognostic importance of MiR-21 in stage II colon cancer: a population-based study. Br. J. Cancer 2012, 107:1169-1174.
25. Li B.L., Lu C., Lu W., Yang T.T., Qu J., Hong X., Wan X.P. MiR-130b is an EMT-related MicroRNA that targets DICER1 for aggression in endometrial cancer. Med. Oncol. 2013, 30:484.
26. Li D., Liu X., Lin L., Hou J., Li N., Wang C., Wang P., Zhang Q., Zhang P., Zhou W., Wang Z., Ding G., Zhuang S.M., Zheng L., Tao W., Cao X. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J. Biol. Chem. 2011, 286:36677-36685.
27. Liang Z., Wu H., Xia J., Li Y., Zhang Y., Huang K., Wagar N., Yoon Y., Cho H.T., Scala S., Shim H. Involvement of MiR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol. 2010, 79:817-824.
28. Link A., Balaguer F., Shen Y., Nagasaka T., Lozano J.J., Boland C.R., Goel A. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers Prev. 2010, 19:1766-1774.
29. Ma Y., Zhang P., Wang F., Zhang H., Yang J., Peng J., Liu W., Qin H. MiR-150 As a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 2012, 61:1447-1453.
30. Mestdagh P., Van V.P., De W.A., Muth D., Westermann F., Speleman F., Vandesompele J. A novel and universal method for MicroRNA RT-QPCR data normalization. Genome Biol. 2009, 10:R64.
31. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating MicroRNAs As stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
32. Monzo M., Navarro A., Bandres E., Artells R., Moreno I., Gel B., Ibeas R., Moreno J., Martinez F., Diaz T., Martinez A., Balague O., Garcia-Foncillas J. Overlapping expression of MicroRNAs in human embryonic colon and colorectal cancer. Cell Res. 2008, 18:823-833.
33. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., Poon T.C., Ng S.S., Sung J.J. Differential expression of MicroRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
34. Pigati L., Yaddanapudi S.C., Iyengar R., Kim D.J., Hearn S.A., Danforth D., Hastings M.L., Duelli D.M. Selective release of MicroRNA species from normal and malignant mammary epithelial cells. PLoS One 2010, 5:e13515.
35. Rasmussen M.H., Jensen N.F., Tarpgaard L.S., Qvortrup C., Romer M.U., Stenvang J., Hansen T.P., Christensen L.L., Lindebjerg J., Hansen F., Jensen B.V., Hansen T.F., Pfeiffer P., Brunner N., Orntoft T.F., Andersen C.L. High expression of MicroRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol. Oncol. 2013, 7:637-646.
36. Saunders M., Iveson T. Management of advanced colorectal cancer: state of the art. Br. J. Cancer 2006, 95:131-138.
37. Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., Yuen S.T., Chan T.L., Kwong D.L., Au G.K., Liu C.G., Calin G.A., Croce C.M., Harris C.C. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
38. Sebastiani G., Grieco F.A., Spagnuolo I., Galleri L., Cataldo D., Dotta F. Increased expression of MicroRNA MiR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab. Res. Rev. 2011, 27:862-866.
39. Takahashi M., Cuatrecasas M., Balaguer F., Hur K., Toiyama Y., Castells A., Boland C.R., Goel A. The clinical significance of MiR-148a As a predictive biomarker in patients with advanced colorectal cancer. PLoS One 2012, 7:e46684.
40. Tazawa H., Tsuchiya N., Izumiya M., Nakagama H. Tumor-suppressive MiR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:15472-15477.
41. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van G.M., van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in Solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92:205-216.
42. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C., de G.A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004, 22:229-237.
43. Tsuchiya Y., Nakajima M., Takagi S., Taniya T., Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006, 66:9090-9098.
44. Tveit K.M., Guren T., Glimelius B., Pfeiffer P., Sorbye H., Pyrhonen S., Sigurdsson F., Kure E., Ikdahl T., Skovlund E., Fokstuen T., Hansen F., Hofsli E., Birkemeyer E., Johnsson A., Starkhammar H., Yilmaz M.K., Keldsen N., Erdal A.B., Dajani O., Dahl O., Christoffersen T. Phase III trial of cetuximab with continuous or intermittent fluorouracil, Leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol. 2012, 30:1755-1762.
45. Vickers M.M., Bar J., Gorn-Hondermann I., Yarom N., Daneshmand M., Hanson J.E., Addison C.L., Asmis T.R., Jonker D.J., Maroun J., Lorimer I.A., Goss G.D., Dimitroulakos J. Stage-dependent differential expression of MicroRNAs in colorectal cancer: potential role As markers of metastatic disease. Clin. Exp. Metastasis 2012, 29:123-132.
46. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A MicroRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2257-2261.
47. Wang F., Zheng Z., Guo J., Ding X. Correlation and quantitation of MicroRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 2010, 119:586-593.
48. Xu J., Zhu X., Wu L., Yang R., Yang Z., Wang Q., Wu F. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/Beta-Catenin Pathway. Liver Int. 2012, 32:752-760.
49. Zhang H., Li Y., Huang Q., Ren X., Hu H., Sheng H., Lai M. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ. 2011, 18:1702-1710.
50. Zheng T., Wang J., Chen X., Liu L. Role of MicroRNA in anticancer drug resistance. Int. J. Cancer 2010, 126:2-10.
51. Zhou J., Zhou Y., Yin B., Hao W., Zhao L., Ju W., Bai C. 5-Fluorouracil and oxaliplatin modify the expression profiles of MicroRNAs in human colon cancer cells in Vitro. Oncol. Rep. 2010, 23:121-128.